VITA 34 AG (V3V) - Net Assets
Based on the latest financial reports, VITA 34 AG (V3V) has net assets worth €12.26 Million EUR (≈ $14.33 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€159.53 Million ≈ $186.51 Million USD) and total liabilities (€147.28 Million ≈ $172.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of VITA 34 AG to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €12.26 Million |
| % of Total Assets | 7.68% |
| Annual Growth Rate | -0.01% |
| 5-Year Change | -56.3% |
| 10-Year Change | -45.67% |
| Growth Volatility | 26.58 |
VITA 34 AG - Net Assets Trend (2006–2024)
This chart illustrates how VITA 34 AG's net assets have evolved over time, based on quarterly financial data. Also explore VITA 34 AG assets under control for the complete picture of this company's asset base.
Annual Net Assets for VITA 34 AG (2006–2024)
The table below shows the annual net assets of VITA 34 AG from 2006 to 2024. For live valuation and market cap data, see V3V company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €12.91 Million ≈ $15.09 Million |
-43.33% |
| 2023-12-31 | €22.77 Million ≈ $26.63 Million |
+43.68% |
| 2022-12-31 | €15.85 Million ≈ $18.53 Million |
-62.21% |
| 2021-12-31 | €41.94 Million ≈ $49.03 Million |
+42.00% |
| 2020-12-31 | €29.54 Million ≈ $34.53 Million |
-2.42% |
| 2019-12-31 | €30.27 Million ≈ $35.39 Million |
+2.44% |
| 2018-12-31 | €29.55 Million ≈ $34.54 Million |
-0.32% |
| 2017-12-31 | €29.64 Million ≈ $34.66 Million |
+25.35% |
| 2016-12-31 | €23.65 Million ≈ $27.65 Million |
-0.45% |
| 2015-12-31 | €23.76 Million ≈ $27.77 Million |
+7.20% |
| 2014-12-31 | €22.16 Million ≈ $25.91 Million |
+4.08% |
| 2013-12-31 | €21.29 Million ≈ $24.89 Million |
+3.89% |
| 2012-12-31 | €20.49 Million ≈ $23.96 Million |
+2.42% |
| 2011-12-31 | €20.01 Million ≈ $23.39 Million |
+6.33% |
| 2010-12-31 | €18.82 Million ≈ $22.00 Million |
-0.29% |
| 2009-12-31 | €18.87 Million ≈ $22.06 Million |
+4.24% |
| 2008-12-31 | €18.11 Million ≈ $21.17 Million |
-8.23% |
| 2007-12-31 | €19.73 Million ≈ $23.07 Million |
+52.52% |
| 2006-12-31 | €12.94 Million ≈ $15.12 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to VITA 34 AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3942600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €17.64 Million | 124.81% |
| Other Comprehensive Income | €-754.00K | -5.33% |
| Other Components | €39.54 Million | 279.75% |
| Total Equity | €14.13 Million | 100.00% |
VITA 34 AG Competitors by Market Cap
The table below lists competitors of VITA 34 AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eaton Vance Senior Income Closed Fund
NYSE:EVF
|
$90.49 Million |
|
Kino Indonesia Tbk PT
JK:KINO
|
$90.49 Million |
|
Canadian Life Companies Split Corp
TO:LFE
|
$90.52 Million |
|
FELIX Gold Ltd
AU:FXG
|
$90.53 Million |
|
Brave C&H Supply Co Ltd
TWO:6538
|
$90.44 Million |
|
CYGNUS Metals Ltd
AU:CY5
|
$90.40 Million |
|
Lily Textile Co Ltd
TW:1443
|
$90.40 Million |
|
M & A EQUITY HOLDINGS BERHAD
KLSE:7082
|
$90.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VITA 34 AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,562,000 to 14,134,000, a change of -9,428,000 (-40.0%).
- Net loss of 12,136,000 reduced equity.
- Dividend payments of 2,000 reduced retained earnings.
- Other comprehensive income increased equity by 1,537,000.
- Other factors increased equity by 1,173,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-12.14 Million | -85.86% |
| Dividends Paid | €2.00K | -0.01% |
| Other Comprehensive Income | €1.54 Million | +10.87% |
| Other Changes | €1.17 Million | +8.3% |
| Total Change | €- | -40.01% |
Book Value vs Market Value Analysis
This analysis compares VITA 34 AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.72x to 5.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | €6.14 | €4.44 | x |
| 2007-12-31 | €7.67 | €4.44 | x |
| 2008-12-31 | €6.63 | €4.44 | x |
| 2009-12-31 | €6.93 | €4.44 | x |
| 2010-12-31 | €6.79 | €4.44 | x |
| 2011-12-31 | €7.25 | €4.44 | x |
| 2012-12-31 | €6.94 | €4.44 | x |
| 2013-12-31 | €6.78 | €4.44 | x |
| 2014-12-31 | €7.08 | €4.44 | x |
| 2015-12-31 | €7.79 | €4.44 | x |
| 2016-12-31 | €7.76 | €4.44 | x |
| 2017-12-31 | €8.32 | €4.44 | x |
| 2018-12-31 | €7.20 | €4.44 | x |
| 2019-12-31 | €7.36 | €4.44 | x |
| 2020-12-31 | €7.21 | €4.44 | x |
| 2021-12-31 | €7.39 | €4.44 | x |
| 2022-12-31 | €1.04 | €4.44 | x |
| 2023-12-31 | €1.48 | €4.44 | x |
| 2024-12-31 | €0.81 | €4.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VITA 34 AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -85.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.77%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 10.81x
- Recent ROE (-85.86%) is below the historical average (-13.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -6.01% | -7.68% | 0.48x | 1.64x | €-3.16 Million |
| 2008 | -9.46% | -11.45% | 0.49x | 1.67x | €-3.52 Million |
| 2009 | 3.16% | 3.95% | 0.48x | 1.65x | €-1.29 Million |
| 2010 | 1.89% | 2.06% | 0.46x | 1.99x | €-1.50 Million |
| 2011 | 6.03% | 7.44% | 0.46x | 1.76x | €-783.10K |
| 2012 | -2.86% | -4.26% | 0.37x | 1.81x | €-2.60 Million |
| 2013 | 3.97% | 6.18% | 0.38x | 1.69x | €-1.27 Million |
| 2014 | 4.98% | 7.98% | 0.37x | 1.68x | €-1.11 Million |
| 2015 | 8.36% | 13.97% | 0.32x | 1.85x | €-388.40K |
| 2016 | 1.73% | 2.50% | 0.38x | 1.84x | €-1.96 Million |
| 2017 | -1.09% | -1.68% | 0.31x | 2.10x | €-3.27 Million |
| 2018 | 2.81% | 4.06% | 0.34x | 2.02x | €-2.11 Million |
| 2019 | 4.48% | 6.67% | 0.33x | 2.03x | €-1.67 Million |
| 2020 | 4.90% | 7.22% | 0.34x | 1.98x | €-1.51 Million |
| 2021 | -9.11% | -13.82% | 0.16x | 4.13x | €-8.23 Million |
| 2022 | -165.98% | -39.72% | 0.46x | 9.18x | €-29.03 Million |
| 2023 | -7.92% | -2.42% | 0.49x | 6.72x | €-4.22 Million |
| 2024 | -85.86% | -14.77% | 0.54x | 10.81x | €-13.55 Million |
Industry Comparison
This section compares VITA 34 AG's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $5,863,591,555
- Average return on equity (ROE) among peers: -73.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VITA 34 AG (V3V) | €12.26 Million | -6.01% | 12.02x | $90.49 Million |
| China Resources Medical Holdings Company Limited (1PH) | $7.01 Billion | 3.67% | 0.95x | $428.88 Million |
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | $-125.88 Million | 0.00% | 0.00x | $3.30 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $10.35 Billion | 2.73% | 0.45x | $720.78 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.34 Billion | 4.88% | 1.24x | $19.18 Million |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $24.10 Billion | 29.08% | 0.21x | $49.31K |
| Eifelhöhen-Klinik AG (EIF) | $9.88 Million | -19.11% | 6.64x | $8.99 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $2.01 Billion | -12.28% | 1.84x | $12.02 Billion |
| Fresenius Medical Care AG & Co. KGaA (FMEA) | $10.83 Billion | 11.82% | 1.22x | $11.58 Billion |
| Fresenius SE & Co. KGaA (FRE) | $3.10 Billion | 10.64% | 3.84x | $27.16 Billion |
About VITA 34 AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and… Read more